Optimization of nanostructured lipid carriers of lamotrigine for brain delivery:in vitrocharacterization andin vivoefficacy in epilepsy

Abstract

Hence we can conclude that IN administration of LMT NLCs in rats is able to maintain higher brain concentration of LMT compared to IN and oral drug solution.

Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting

“…All these features are desirable for efficient N2B delivery and represent critical issues toward the effective application of drugs that per se (i.e., without a carrier) would not achieve CNS concentrations leading to a pharmacological effect. Therefore, almost any pharmaceutical nanocarrier has been studied for nose-to-brain delivery, including nanocrystals [ 41 , 42 ], micelles [ 43 , 44 ], liposomes [ 45 ], solid lipid nanoparticles (SLN) [ 46 , 47 ], nanostructured lipid carriers (NLC) [ 48 , 49 ], polymeric nanoparticles [ 50 , 51 , 52 ], albumin nanoparticles [ 53 ], gelatin nanoparticles [ 53 ], dendrimers [ 54 ], mesoporous silica nanoparticles [ 55 ], nanoemulsions [ 56 ].…”

Chemical engineering of a lipid nano-scaffold for the solubility enhancement of an antihyperlipidaemic drug, simvastatin; preparation, optimization, physicochemical characterization and pharmacodynamic study

“…Simvastatin was dissolved by stirring in molten lipid to form a uniform and clear oil phase. An aqueous phase was prepared by dissolving Poloxamer188 in double distilled water (sufficient to produce 10 mL of preparation) and heated to the same temperature as the oil phase [14]. The hot aqueous phase was added dropwise to the oil phase with continuous stirring at 600 rpm for 10 min.…”

Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain

“…The direct brain entry of PHT aer IN administration could be attributed to the surfactant tween 80, which was shown to improve the penetration of drug through nasal mucosa. 54 Additionally, the positive charge and mucoadhesive properties of chitosan, could also facilitate the direct entry to the brain through the nasal mucosa as previously demonstrated. 25,55 For example, carboxymethyl chitosan NPs were used as a carrier to deliver carbamazepine via the IN route.…”

“…As such, the use of chitosan as a mucoadhesive polymer in NPs was essential to achieve this direct delivery to the brain, which was probably dependent on the increase in residence time within the nasal cavity and avoiding the systemic circulation and/or pharynx drainage. 24,54 Additionally, the level of PHT was high in the plasma in the early time points aer IP administration. This is consistent with the pharmacokinetic prole of PHT following systemic administration and its ability to cross the BBB as a small lipophilic molecule (log P 2.47).…”